CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

EpiVax führt KI-gestützte Modelle zur Vorhersage der Immunogenität ein

ISPRI™Positive
AI Analysis

Summary

EpiVax announces AI-enhanced extensions to its ISPRI proprietary platform for assessing immunogenicity risk in biotherapeutics. The upgrade introduces new capabilities to the in-silico assessment platform.

Importance:3/10
Sentiment:
0.60
AI/MLPlatformImmunogenicityTechnologyIn-silico

Read the original article

Published by PR Newswire Pharma on September 3, 2026 5:22 AM

Read Original